Close Menu
Jeremy M . Shefner, MD, PhD

Professor

Contact

JeremyShefner@creighton.edu
School of Medicine

Jeremy M . Shefner, MD, PhD

Professor

Department

Neurology (Phoenix)

Position

Professor

Books

  • Elsevier
    Andrews JA, Shefner JM. Clinical neurophysiology of anterior horn cell disorders. Handbook of Clinical Neurology.
    Volume 161, Chapter 20, p. 317-326 2019

Publications

  • Neurology
    Andrews JA, Bruijn LI, Shefner JM. ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment.
    Volume 93, Issue 2, p. 66-71 2019
  • Neurology
    Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, Xia S, Bennett CF,Bishop KM, Shefner JM, Green AM, Sun P, Bhan I, Gheuens S, Schneider E, Farwell W, De Vivo DC;ISIS-396443-CS2/ISIS-396443-CS12 Study Groups. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
    Volume 92, Issue 21, p. e2492-e2506 2019
  • Journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
    Shefner JM, Cudkowicz ME, Hardiman O, Cockroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.
    Volume 20, Issue 7-8, p. 584-594 2019
  • Neurology
    Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, Xia S, Bennett CF, Bishop KM, Shefner JM, Green AM, Sun P, Bhan I, Gheuens S, Schneider E, Farwell W, De Vivo DC. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
    Volume 92, Issue 21, p. e2492-e2506 2019
  • Journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
    Rutkove SB, Qi K, Shelton K, Liss J, Berisha V, Shefner JM. ALS longitudinal studies with frequent data collection at home: study design and baseline data.
    Volume 20, Issue 1-2, p. 61-67 2018
  • Journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
    Shefner JM, Rutkove SB, Caress JB, Benatar M, David WS, Cartwright MC, Macklin EA, Bohorquez JL. Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system.
    Volume 19, Issue 7-8, p. 555-561 2018
  • Muscle & Nerve

    Volume 59, Issue 1, p. 6-7 2018
  • American Journal of Managed Care
    Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.
    Volume 24, p. S175-S186 2018
  • European Journal of Neurology
    Smith RA, Macklin EA, Myers KJ, Pattee GL, Goslin KL, Meekins GD, Green JR, Shefner JM, Pioro EP. Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale).
    Volume 25, Issue 7, p. 907-e66 2018
  • Journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
    Lechtzin N, Cudkowicz ME, de Carvalho M, Genge A, Hardiman O, Mitsumoto H, Mora JS, Shefner J, Van den Berg LH, Andrews JA. Respiratory measures in amyotrophic lateral sclerosis. 
    Volume 19, Issue 5-6, p. 321-330 2018
  • Journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
    Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.
    Volume 19, Issue 3-4, p. 259-266 2018
  • JAMA Neurology
    Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, Malik FI, Shefner JM. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.
    Volume 75, Issue 1, p. 58-64 2017
  • Journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
    Meng L, Bian A, Jordan S, Wolff A, Shefner JM, Andrews J. Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance.
    Volume 19, Issue 1-2, p. 134-142 2017

Presentations

  • Invited Speaker, 2019 California ALS Summit, Irvine CA. 2019
  • Invited Speaker, 2018 Northeast ALS Clinical Trials Consortium Annual Meeting, Clearwater FL. 2018
  • Plenary Speaker, 2018 FightMND Australasion ALS Symposium, Melbourne, Australia. 2018
  • Lisa Krivickas Lecturer, Massachusetts General Hospital, Boston, MA. 2018
  • Invited Speaker, Packard Symposium on ALS, Baltimore, MD. 2017
  • Grand Rounds, Houston Methodist Medical Center. 2017
  • Grand Rounds, University of Arizona College of Medicine. 2017

Other

  • Speech Analysis in ALS Patients with and without Cognitive Abnormalities: Evaluation of Sensitivity and Disease Progression

  • Treat ALS NEALS Clinical Trials Network. Goal: to facilitate the performance of investigator initiated ALS trials.

  • A Phase 2 study of CK107 in Patients with Amyotrophic Lateral Sclerosis (ALS) Goal: To determine the safety and preliminary efficacy of treatment of CK107 in ALS patients.

  • Fluid Biomarkers with Deep Phenotyping in Patients with ALS. Goal: To discover fluid markers that correlate with specific aspects of decline in ALS patients.

  • ALS AT HOME: Measuring ALS Progression using home based outcome measures. Goal: to reduce variability of standard outcome measures using frequent sampling and to test a paradigm whereby patients can participate in clinical trials remote from a study site.

};